Early Access Program of Lazertinib in Republic of Korea

Launched by YUHAN CORPORATION · Mar 30, 2021

Keywords

ClinConnect Summary

Lazertinib is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.

This is a Multi-center, Prospective, Early Access Program of Lazertinib in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with T790M mutation-positive after 1st/2nd generation EGFR TKIs therapy to assess the safety and efficacy of real world evidence as second-line treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged at least 19 years
• • Patients who have written consent for use of personal and medical information for the study purpose
• • Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously.
• Exclusion Criteria:
• • Patients with hypersensitivity to Lazertinib or its any ingredients
• • Patients who belong to contraindication listed on lazertinib label in Korea
• • Patients who are treated for an indication not approved for the use of Lazertinib
• • Women who are pregnant or may possibly become pregnant